Solitary plasmacytoma: Lenalidomide-Dexamethasone combined with radiation therapy improves progression-free survival and multiple myeloma-free survival

To evaluate the results of the concurrent use of lenalidomide-dexamethasone with intensity-modulated radiation therapy (IMRT) for solitary plasmacytoma in terms of toxicity and outcomeMaterials& Methods: Forty-six patients were treated for histologically proven SP between June 2007 and June 2018 in our Department (XXX). All patients received IMRT. The median total dose was 40 Gy (range, 40-46). Prescription of concurrent lenalidomide-dexamethasone with radiotherapy was left discretion of the referring hematologist-oncologist and started the first day of radiotherapy for four cycles.

Source: International Journal of Radiation Oncology * Biology * Physics - November 6, 2019 Category: Radiology Authors: Fabien Mignot, Antoine Schernberg, Alexandre Ars ène-Henry, Marguerite Vignon, Didier Bouscary, Youlia Kirova Source Type: research